Psoriasis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Psoriasis – Pipeline Review, H1 2017’, provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Psoriasis

– The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects

– The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Psoriasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Psoriasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

Abeome Corp

AbGenomics International Inc

Addex Therapeutics Ltd

Adello Biologics LLC

Advinus Therapeutics Ltd

Affibody AB

Albireo Pharma Inc

Alfacyte Ltd

Allergan Plc

Almirall SA

Alteogen Inc

Alvotech Iceland

Amgen Inc

Anacor Pharmaceuticals Inc

AnaptysBio Inc

ApoPharma Inc

Arbor Pharmaceuticals LLC

Arena Pharmaceuticals Inc

Argos Therapeutics Inc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Athenex Inc

Atlantic Bio Sci LLC

Aurigene Discovery Technologies Ltd

Aurinia Pharmaceuticals Inc

Bayer AG

Beta Pharma Inc

BioApex sro

Biocad

Biocon Ltd

BioLingus AG

BioMAS Ltd

Biomics Biotechnologies Co Ltd

Bionomics Ltd

Bionovis SA

BirchBioMed Inc

Boehringer Ingelheim GmbH

Brickell Biotech Inc

Bristol-Myers Squibb Company

C4X Discovery Holdings PLC

CalciMedica Inc

Can-Fite BioPharma Ltd

Celgene Corp

Cell Medica Ltd

Cellceutix Corp

ChemoCentryx Inc

Chipscreen Biosciences Ltd

ChironWells GmbH

Coherus BioSciences Inc

Compugen Ltd

Concenter BioPharma Silkim Ltd

Crescita Therapeutics Inc

CritiTech Inc

Curapel Ltd

Dermala Inc

Dr. August Wolff GmbH & Co KG Arzneimittle

DURECT Corp

EA Pharma Co Ltd

Eli Lilly and Company

ELORAC Inc

Exicure Inc

Foamix Pharmaceuticals Ltd

Forward Pharma A/S

Galapagos NV

Galderma SA

Galectin Therapeutics Inc

Gem Pharmaceuticals LLC

Genentech Inc

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

GlycoMar Ltd

Grupo Ferrer Internacional SA

HitGen LTD

Huabo Biopharm Co Ltd

Hydra Biosciences Inc

iCo Therapeutics Inc.

Immune Pharmaceuticals Inc

Immune Response BioPharma Inc

Immungenetics AG

Immunwork Inc

Japan Tobacco Inc

Jenrin Discovery Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kadmon Corp LLC

KaloBios Pharmaceuticals Inc

Kang Stem Biotech Co Ltd

KPI Therapeutics Inc

Lead Pharma Holding BV

LEO Pharma A/S

Lupin Ltd

Lycera Corp

mAbxience SA

Maruho Co Ltd

Medestea Research & Production SpA

MediGene AG

Merck KGaA

MetrioPharm AG

Mitsubishi Tanabe Pharma Corp

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

Nimbus Therapeutics LLC

NovaLead Pharma Pvt Ltd

Novan Inc

Novartis AG

Nuevolution AB

Numab Innovation AG

Oncobiologics Inc

OSE Immunotherapeutics

Panacea Biotec Ltd

Pfizer Inc

Pharis Biotec GmbH

Pharmedartis GmbH

Philogen SpA

PinCell srl

Principia Biopharma Inc

Promius Pharma LLC

Protalix BioTherapeutics Inc

Prothena Corp Plc

Provectus Biopharmaceuticals Inc

Qilu Pharmaceutical Co Ltd

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Rigel Pharmaceuticals Inc

Rock Creek Pharmaceuticals, Inc.

Samumed LLC

Sandoz International GmbH

Sareum Holdings Plc

SBI Biotech Co Ltd

Shulov Innovative Science Ltd

Sigmoid Pharma Ltd

Soligenix Inc

Spherium Biomed SL

sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd

SWITCH Biotech LLC

Syntrix Biosystems Inc

Takeda Pharmaceutical Company Ltd

Tasly Pharmaceutical Group Co Ltd

Teva Pharmaceutical Industries Ltd

TheraMAB LLC

Tolero Pharmaceuticals Inc

UCB SA

Valeant Pharmaceuticals International Inc

vTv Therapeutics Inc

Wellstat Therapeutics Corp

XBiotech Inc

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Psoriasis - Overview 9

Psoriasis - Therapeutics Development 10

Psoriasis - Therapeutics Assessment 39

Psoriasis - Companies Involved in Therapeutics Development 55

Psoriasis - Drug Profiles 130

Psoriasis - Discontinued Products 607

Psoriasis - Product Development Milestones 610

Appendix 619

List of Tables

List of Tables

Number of Products under Development for Psoriasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Psoriasis – Pipeline by 3SBio Inc, H1 2017

Psoriasis – Pipeline by AbbVie Inc, H1 2017

Psoriasis – Pipeline by Abeome Corp, H1 2017

Psoriasis – Pipeline by AbGenomics International Inc, H1 2017

Psoriasis – Pipeline by Addex Therapeutics Ltd, H1 2017

Psoriasis – Pipeline by Adello Biologics LLC, H1 2017

Psoriasis – Pipeline by Advinus Therapeutics Ltd, H1 2017

Psoriasis – Pipeline by Affibody AB, H1 2017

Psoriasis – Pipeline by Albireo Pharma Inc, H1 2017

Psoriasis – Pipeline by Alfacyte Ltd, H1 2017

Psoriasis – Pipeline by Allergan Plc, H1 2017

Psoriasis – Pipeline by Almirall SA, H1 2017

Psoriasis – Pipeline by Alteogen Inc, H1 2017

Psoriasis – Pipeline by Alvotech Iceland, H1 2017

Psoriasis – Pipeline by Amgen Inc, H1 2017

Psoriasis – Pipeline by Anacor Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by AnaptysBio Inc, H1 2017

Psoriasis – Pipeline by ApoPharma Inc, H1 2017

Psoriasis – Pipeline by Arbor Pharmaceuticals LLC, H1 2017

Psoriasis – Pipeline by Arena Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by Argos Therapeutics Inc, H1 2017

Psoriasis – Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Psoriasis – Pipeline by AstraZeneca Plc, H1 2017

Psoriasis – Pipeline by Athenex Inc, H1 2017

Psoriasis – Pipeline by Atlantic Bio Sci LLC, H1 2017

Psoriasis – Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Psoriasis – Pipeline by Aurinia Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by Bayer AG, H1 2017

Psoriasis – Pipeline by Beta Pharma Inc, H1 2017

Psoriasis – Pipeline by BioApex sro, H1 2017

Psoriasis – Pipeline by Biocad, H1 2017

Psoriasis – Pipeline by Biocon Ltd, H1 2017

Psoriasis – Pipeline by BioLingus AG, H1 2017

Psoriasis – Pipeline by BioMAS Ltd, H1 2017

Psoriasis – Pipeline by Biomics Biotechnologies Co Ltd, H1 2017

Psoriasis – Pipeline by Bionomics Ltd, H1 2017

Psoriasis – Pipeline by Bionovis SA, H1 2017

Psoriasis – Pipeline by BirchBioMed Inc, H1 2017

Psoriasis – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Psoriasis – Pipeline by Brickell Biotech Inc, H1 2017

Psoriasis – Pipeline by Bristol-Myers Squibb Company, H1 2017

Psoriasis – Pipeline by C4X Discovery Holdings PLC, H1 2017

Psoriasis – Pipeline by CalciMedica Inc, H1 2017

Psoriasis – Pipeline by Can-Fite BioPharma Ltd, H1 2017

Psoriasis – Pipeline by Celgene Corp, H1 2017

Psoriasis – Pipeline by Cell Medica Ltd, H1 2017

Psoriasis – Pipeline by Cellceutix Corp, H1 2017

Psoriasis – Pipeline by ChemoCentryx Inc, H1 2017

Psoriasis – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Psoriasis – Pipeline by ChironWells GmbH, H1 2017

Psoriasis – Pipeline by Coherus BioSciences Inc, H1 2017

Psoriasis – Pipeline by Compugen Ltd, H1 2017

Psoriasis – Pipeline by Concenter BioPharma Silkim Ltd, H1 2017

Psoriasis – Pipeline by Crescita Therapeutics Inc, H1 2017

Psoriasis – Pipeline by CritiTech Inc, H1 2017

Psoriasis – Pipeline by Curapel Ltd, H1 2017

Psoriasis – Pipeline by Dermala Inc, H1 2017

Psoriasis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017

Psoriasis – Pipeline by DURECT Corp, H1 2017

Psoriasis – Pipeline by EA Pharma Co Ltd, H1 2017

Psoriasis – Pipeline by Eli Lilly and Company, H1 2017

Psoriasis – Pipeline by ELORAC Inc, H1 2017

Psoriasis – Pipeline by Exicure Inc, H1 2017

Psoriasis – Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Psoriasis – Pipeline by Forward Pharma A/S, H1 2017

Psoriasis – Pipeline by Galapagos NV, H1 2017

Psoriasis – Pipeline by Galderma SA, H1 2017

Psoriasis – Pipeline by Galectin Therapeutics Inc, H1 2017

Psoriasis – Pipeline by Gem Pharmaceuticals LLC, H1 2017

Psoriasis – Pipeline by Genentech Inc, H1 2017

Psoriasis – Pipeline by Genor BioPharma Co Ltd, H1 2017

Psoriasis – Pipeline by GlaxoSmithKline Plc, H1 2017

Psoriasis – Pipeline by GlycoMar Ltd, H1 2017

Psoriasis – Pipeline by Grupo Ferrer Internacional SA, H1 2017

Psoriasis – Pipeline by HitGen LTD, H1 2017

Psoriasis – Pipeline by Huabo Biopharm Co Ltd, H1 2017

Psoriasis – Pipeline by Hydra Biosciences Inc, H1 2017

Psoriasis – Pipeline by iCo Therapeutics Inc., H1 2017

Psoriasis – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by Immune Response BioPharma Inc, H1 2017

Psoriasis – Pipeline by Immungenetics AG, H1 2017

Psoriasis – Pipeline by Immunwork Inc, H1 2017

Psoriasis – Pipeline by Japan Tobacco Inc, H1 2017

Psoriasis – Pipeline by Jenrin Discovery Inc, H1 2017

Psoriasis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Psoriasis – Pipeline by Johnson & Johnson, H1 2017

Psoriasis – Pipeline by Kadmon Corp LLC, H1 2017

Psoriasis – Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by Kang Stem Biotech Co Ltd, H1 2017

Psoriasis – Pipeline by KPI Therapeutics Inc, H1 2017

Psoriasis – Pipeline by Lead Pharma Holding BV, H1 2017

Psoriasis – Pipeline by LEO Pharma A/S, H1 2017

Psoriasis – Pipeline by Lupin Ltd, H1 2017

Psoriasis – Pipeline by Lycera Corp, H1 2017

Psoriasis – Pipeline by mAbxience SA, H1 2017

Psoriasis – Pipeline by Maruho Co Ltd, H1 2017

Psoriasis – Pipeline by Medestea Research & Production SpA, H1 2017

Psoriasis – Pipeline by MediGene AG, H1 2017

Psoriasis – Pipeline by Merck KGaA, H1 2017

Psoriasis – Pipeline by MetrioPharm AG, H1 2017

Psoriasis – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Psoriasis – Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by Mycenax Biotech Inc, H1 2017

Psoriasis – Pipeline by Nimbus Therapeutics LLC, H1 2017

Psoriasis – Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Psoriasis – Pipeline by Novan Inc, H1 2017

Psoriasis – Pipeline by Novartis AG, H1 2017

Psoriasis – Pipeline by Nuevolution AB, H1 2017

Psoriasis – Pipeline by Numab Innovation AG, H1 2017

Psoriasis – Pipeline by Oncobiologics Inc, H1 2017

Psoriasis – Pipeline by OSE Immunotherapeutics, H1 2017

Psoriasis – Pipeline by Panacea Biotec Ltd, H1 2017

Psoriasis – Pipeline by Pfizer Inc, H1 2017

Psoriasis – Pipeline by Pharis Biotec GmbH, H1 2017

Psoriasis – Pipeline by Pharmedartis GmbH, H1 2017

Psoriasis – Pipeline by Philogen SpA, H1 2017

Psoriasis – Pipeline by PinCell srl, H1 2017

Psoriasis – Pipeline by Principia Biopharma Inc, H1 2017

Psoriasis – Pipeline by Promius Pharma LLC, H1 2017

Psoriasis – Pipeline by Protalix BioTherapeutics Inc, H1 2017

Psoriasis – Pipeline by Prothena Corp Plc, H1 2017

Psoriasis – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by Qilu Pharmaceutical Co Ltd, H1 2017

Psoriasis – Pipeline by RedHill Biopharma Ltd, H1 2017

Psoriasis – Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Psoriasis – Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017

Psoriasis – Pipeline by Samumed LLC, H1 2017

Psoriasis – Pipeline by Sandoz International GmbH, H1 2017

Psoriasis – Pipeline by Sareum Holdings Plc, H1 2017

Psoriasis – Pipeline by SBI Biotech Co Ltd, H1 2017

Psoriasis – Pipeline by Shulov Innovative Science Ltd, H1 2017

Psoriasis – Pipeline by Sigmoid Pharma Ltd, H1 2017

Psoriasis – Pipeline by Soligenix Inc, H1 2017

Psoriasis – Pipeline by Spherium Biomed SL, H1 2017

Psoriasis – Pipeline by sterna biologicals Gmbh & Co KG, H1 2017

Psoriasis – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Psoriasis – Pipeline by SWITCH Biotech LLC, H1 2017

Psoriasis – Pipeline by Syntrix Biosystems Inc, H1 2017

Psoriasis – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Psoriasis – Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Psoriasis – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Psoriasis – Pipeline by TheraMAB LLC, H1 2017

Psoriasis – Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Psoriasis – Pipeline by UCB SA, H1 2017

Psoriasis – Pipeline by Valeant Pharmaceuticals International Inc, H1 2017

Psoriasis – Pipeline by vTv Therapeutics Inc, H1 2017

Psoriasis – Pipeline by Wellstat Therapeutics Corp, H1 2017

Psoriasis – Pipeline by XBiotech Inc, H1 2017

Psoriasis – Pipeline by Yuhan Corp, H1 2017

Psoriasis – Dormant Projects, H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..1), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..2), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..3), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..4), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..5), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..6), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..7), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..8), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..9), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..10), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..11), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..12), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..13), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..14), H1 2017

Psoriasis – Dormant Projects, H1 2017 (Contd..15), H1 2017

Psoriasis – Discontinued Products, H1 2017

Psoriasis – Discontinued Products, H1 2017 (Contd..1), H1 2017

Psoriasis – Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development for Acromegaly, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports